Arrowhead   Pharmaceuticals  misses Q1 revenue estimates

Arrowhead Pharmaceuticals

05/02/2026 21:12

Overview

RNAi therapeutics firm's fiscal Q1 revenue rose but missed analyst expectations

Company launched first commercial product, REDEMPLO, in the U.S.

Company closed public offerings raising $930 mln, improving financial position

Outlook

Arrowhead anticipates REDEMPLO will be marketed independently in Canada later this year

Company plans to advance RNAi therapeutics for cardiovascular disease and tauopathies

Arrowhead expects to leverage improved financial position for program advancements

Result Drivers

REDEMPLO LAUNCH - Arrowhead launched its first commercial product, REDEMPLO, in the U.S. and received regulatory approvals in China and Canada, contributing to revenue growth

OBESITY PROGRAMS - Encouraging early results from obesity programs, including significant weight loss and fat reduction in trials, were reported

FINANCIAL POSITION - Arrowhead improved its financial position with $930 mln raised from public offerings and a $200 mln milestone payment from Sarepta Therapeutics

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$264.03 mln
$270.07 mln (9 Analysts)
Q1 EPS
$0.22
Q1 Net Income
-$2.57 mln
Q1 Operating Expenses
$223.22 mln
Q1 Operating Income
$40.81 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $81.00, about 19% above its February 4 closing price of $68.06

Press Release: ID:nBw9ZYjda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)